



SUPROFENAC NON-STEROIDAL ANTI-INFLAMMATORY

Opportunity

CIS Pharma has developed Suprofenac, a new non-steroidal anti-inflammatory (NSAID) compound for the treatment of acute and chronic pain as well as ocular inflammation. NewCo, an investment vehicle based in Switzerland, acquires the rights for the development and commercial exploitation of Suprofenac. CIS Pharma has established business relationships with contract CRO's and created the intellectual property development plan combined with a high profile management team. NewCo offers company stock against outside investment participation for the purpose of advancing the technology through the clinical phases I and II.

Technology

Pro-Drug Technology, Oral and Transdermal Delivery, Ocular Indication

Suprofenac is a diclofenac derivative that is optimized for target specific transdermal delivery. Acute and especially patients with chronic pain will benefit from the relatively low toxicity of a Suprofenac transdermal patch application in comparison to orally administered diclofenac sodium currently on the market.



Suprofenac Transdermal Patch

Suprofenac is rapidly metabolized in-vivo into diclofenac sodium, identical to form of the orally administered compound (Cataflam®, Voltaren®).

Suprofenac pro-drug also allows for an enhanced transcorneal delivery of diclofenac. Therefore Suprofenac also includes post-surgical and other ocular inflammation conditions.



Suprofenac Ocular Anti-inflammatory

Relatively Low-Risk and Short-Time Development

Based on the known toxicity and pharmacokinetic profile of diclofenac sodium the development risks for Suprofenac are relatively low. Pre-IND correspondence with the FDA and consulting with CRO's have determined a development plan of 32 months including short clinical phases I and II.

Indication and Markets

The main indications for Suprofenac are back pain, arthritis and sports injuries. Currently NSAIDs are a \$6bio market, with topical analgesics at \$740mio. If consumers and practitioners associate Vioxx's risk with all COX-2 drugs (6.3bio) they will turn to NSAIDs and especially to target-specific drugs with less side-effects such as Supro-

fenac. Ocular anti-inflammatory is a \$450mio market.

Intellectual Property Rights

The patent application is underway. The IP rights are granted to NewCo by a trade-customary Licensing Agreement.

CIS Pharma

CIS Pharma is a pharmaceutical research company. It is located in Bubendorf, Switzerland, in the vicinity of Basel. The key business of CIS Pharma is to discover novel active pharmaceutical ingredients and medical devices. For over 50 years, CIS Pharma has been licensing innovative technologies to a wide range of life sciences companies. In co-operation with its development partners CIS Pharma offers the full range of drug discovery, drug development and commercial manufacturing of active pharmaceutical ingredients.

Contact

CIS Pharma welcomes your interest in Suprofenac non-steroidal anti-inflammatory. For business and development plan please contact

Christoph Schäfer, MBA
Bus. Development, Licensing

+41 61 935 53 23
Christoph.Schaefer@cis-pharma.com